tolrestat has been researched along with Cataract in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boldrini, E; Da Settimo, A; Da Settimo, F; Greco, G; La Motta, C; Lavecchia, A; Novellino, E; Primofiore, G; Simorini, F; Taliani, S | 1 |
| Boldrini, E; Da Settimo, A; Da Settimo, F; Greco, G; La Motta, C; Lavecchia, A; Novellino, E; Primofiore, G; Simorini, F | 1 |
| Dicioccio, AT; Geraci, LS; Gunn, DE; Jacot, JL; Jones, JH; Jones, ML; Mitschler, A; Petrova, T; Podjarny, AD; Sawicki, DR; Sredy, J; Van Zandt, MC | 1 |
| Da Settimo, F; La Motta, C; Limongelli, V; Marinelli, L; Marini, AM; Novellino, E; Salerno, S; Sartini, S; Simorini, F; Taliani, S | 1 |
| Behera, P; Sahoo, PK | 1 |
| Bhatnagar, A; Ramana, KV; Srivastava, SK | 1 |
| Cunnick, J; Gonzalez, K; Takemoto, DJ; Udovichenko, I | 1 |
| Tomlinson, DR | 1 |
| Lou, MF; Xu, GT; York, B; Zigler, S | 1 |
| Kador, PF; Lee, YS; Sato, S; Sugiyama, K | 1 |
| Banditelli, S; Boldrini, E; Cappiello, M; Cecconi, I; Dal Monte, M; Del Corso, A; Marini, I; Mura, U; Vilardo, PG | 1 |
| Blessing, K; Fujisawa, S; Kador, PF; Lee, JW; Lou, MF | 1 |
| Azal, O; Baydar, A; Cakir, B; Corakçi, A; Güler, S; Kutlu, M; Yönem, A | 1 |
| Akagi, Y; Dvornik, D; Gonzalez, R; Kador, PF; Kinoshita, JH; Robison, WG | 1 |
| Kador, PF; Kinoshita, JH; Sharpless, NE | 1 |
| Dvornik, D; Gonzalez, R; Greselin, E; Simard-Duquesne, N | 1 |
3 review(s) available for tolrestat and Cataract
| Article | Year |
|---|---|
Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetes Complications; Humans; Imidazolidines; Models, Molecular; Naphthalenes; Oxidation-Reduction; Oxidative Stress; Signal Transduction | 2005 |
Aldose reductase inhibitors and the complications of diabetes mellitus.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Humans; Kidney; Naphthalenes; Rats | 1993 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; Corneal Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Models, Animal; Fluorenes; Galactose; Humans; Hydantoins; Imidazoles; Imidazolidines; Models, Molecular; Naphthalenes; Phthalazines; Rhodanine; Sorbitol; Structure-Activity Relationship; Substrate Specificity; Sugar Alcohol Dehydrogenases; Thiazolidines; Tissue Distribution | 1985 |
13 other study(ies) available for tolrestat and Cataract
| Article | Year |
|---|---|
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
Topics: Acetates; Aldehyde Reductase; Animals; Benzimidazoles; Binding Sites; Cataract; Enzyme Inhibitors; Galactosemias; Humans; Models, Molecular; Ophthalmic Solutions; Protein Binding; Rats; Stereoisomerism; Structure-Activity Relationship; Triazines | 2001 |
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
Topics: Acetates; Aldehyde Reductase; Animals; Cataract; Enzyme Inhibitors; Galactosemias; Humans; Indoles; Models, Molecular; Ophthalmic Solutions; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2003 |
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Topics: Aldehyde Reductase; Animals; Cataract; Chronic Disease; Crystallography, X-Ray; Diabetes Complications; Diabetes Mellitus, Experimental; Humans; Indoleacetic Acids; Lens, Crystalline; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Structure-Activity Relationship; Thiazoles; Tissue Distribution | 2005 |
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
Topics: Acetates; Administration, Topical; Aldehyde Reductase; Animals; Binding Sites; Cataract; Galactosemias; Models, Molecular; Ophthalmic Solutions; Oxadiazoles; Oxazoles; Protein Binding; Protein Conformation; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2008 |
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
Topics: Acetic Acid; Aldehyde Reductase; Animals; Benzimidazoles; Cataract; Disease Models, Animal; Enzyme Inhibitors; Galactosemias; Inhibitory Concentration 50; Molecular Structure; Naphthalenes; Ophthalmic Solutions; Rats | 2010 |
Protein kinase C in galactosemic and tolrestat-treated lens epithelial cells.
Topics: Aldehyde Reductase; Amino Acid Sequence; Animals; Blotting, Western; Cataract; Cattle; Cells, Cultured; Culture Media; Epithelium; Galactose; Isoenzymes; Lens, Crystalline; Molecular Sequence Data; Naphthalenes; Peptides; Protein Kinase C | 1993 |
Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
Topics: Aldehyde Reductase; Animals; Cataract; Culture Techniques; Disease Models, Animal; Enzyme Inhibitors; Fluorenes; Galactose; Hydantoins; Imidazoles; Imidazolidines; Male; Naphthalenes; Rats; Spiro Compounds | 1996 |
Prevention of naphthalene-1,2-dihydrodiol-induced lens protein modifications by structurally diverse aldose reductase inhibitors.
Topics: Aldehyde Reductase; Animals; Cataract; Chromatography, High Pressure Liquid; Crystallins; Enzyme Inhibitors; Fluorenes; Hydantoins; Imidazoles; Imidazolidines; Lens, Crystalline; Naphthalenes; Naphthols; Naphthoquinones; Phthalazines; Rats; Spectrophotometry | 1999 |
A new approach against sugar cataract through aldose reductase inhibitors.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Enzyme Inhibitors; Galactitol; Galactose; Lens, Crystalline; Naphthalenes; Rats; Rats, Sprague-Dawley | 1999 |
Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
Topics: Aldehyde Reductase; Animals; Cataract; Crystallins; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Fluorenes; Glutathione; Glycation End Products, Advanced; Glycosylation; Hydantoins; Lens, Crystalline; Naphthalenes; Phthalazines; Rats; Rats, Sprague-Dawley; Sorbitol; Spectrometry, Fluorescence | 2000 |
Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diabetic Retinopathy; Diuresis; Enzyme Inhibitors; Guanidines; Kidney; Male; Naphthalenes; Nitric Oxide Synthase; Organ Size; Rats; Rats, Sprague-Dawley; Reference Values | 2002 |
Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat.
Topics: Aldehyde Reductase; Animals; Basement Membrane; Capillaries; Cataract; Diabetic Retinopathy; Galactose; Male; Microscopy, Electron; Naphthalenes; Rats; Rats, Inbred Strains; Retinal Vessels; Sugar Alcohol Dehydrogenases | 1986 |
Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat.
Topics: Animals; Cataract; Dose-Response Relationship, Drug; Galactitol; Galactose; Galactosemias; Humans; Lens, Crystalline; Male; Naphthalenes; Rats | 1985 |